Crisugabalin Besilate - Haisco Pharmaceutical Group
Alternative Names: HSK-16149Latest Information Update: 28 Jan 2026
At a glance
- Originator Haisco Pharmaceutical Group
- Class Analgesics; Small molecules; Urologics
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuropathic pain; Postherpetic neuralgia
- Phase II Neuralgia; Postoperative pain
- No development reported Diabetic neuropathies
Most Recent Events
- 28 Jan 2026 Launched for Neuropathic pain in China (PO) (Haisco Pharmaceutical Pipeline, January 2026)
- 28 Jan 2026 Launched for Postherpetic neuralgia in China (PO) (Haisco Pharmaceutical Pipeline, January 2026)
- 25 Jan 2026 Registered for Postherpetic neuralgia in China (PO) (Haisco Pharmaceutical Pipeline, January 2026)